Results 81 to 90 of about 22,047 (159)

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center

Gynecologic Oncology Reports
Objective: A recent clinical trial demonstrated that the use of apixaban was safe and equal to enoxaparin (LMWH) in post-operative gynecologic oncology patients.
Victoria Diamond, Katherine Gerber, Geno Merli, Rebecca Mercier, Aaron Shafer, Norman Rosenblum   +5 more
doaj   +1 more source

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence

Drug Design, Development and Therapy, 2014
Ali Zalpour,1 Thein Hlaing Oo21Division of Pharmacy – Clinical Programs, 2Section of Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Anticoagulation with heparin and vitamin K ...
Zalpour A, Oo TH
doaj  

Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.

PLoS ONE
BackgroundCatheter ablation in patients with atrial fibrillation is associated with a transient increase in thromboembolic risk and adequate anticoagulation is highly important.
Rachel Aakerøy, Jan Pål Loennechen, Roar Dyrkorn, Stian Lydersen, Arne Helland, Olav Spigset   +5 more
doaj   +1 more source

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single-Centre Tertiary Hospital. [PDF]

Australas J Ageing
Creeper KJ, Lenaghan G, Stockwell A, Schmidt M, Ingram K, Stafford AC.   +5 more
europepmc   +1 more source

Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and <i>in silico</i> docking. [PDF]

Front Pharmacol
Onar LC, Guner E, Yilmaz I.
europepmc   +1 more source

Acetylsalicylic acid use for artial fibrillation and bleeding risk. [PDF]

Can Fam Physician
Braschi É, Young J.
europepmc   +1 more source

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis. [PDF]

Ren Fail
Wu X, Meng J, Yang Y, Sheng D, Liu X, Zhou Y.   +5 more
europepmc   +1 more source

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin. [PDF]

Cancers (Basel)
Baghdadi MA, do Carmo Las Casas PHF, Mbemba E, Rousseau A, Kempaiah P, Svistunov AA, Bitsadze V, Sabbah M, Fareed J, Van Dreden P, Trachana V, Lefkou E, Gerotziafas G.   +12 more
europepmc   +1 more source

Apixaban versus warfarin for anticoagulation after left ventricular assist device implantation: A multicenter real-world analysis. [PDF]

JHLT Open
Truong VT, Chilingarashvili G, Mondal A, Raymond T, Pham S, O'Brien T, Chung ES, Egnaczyk GF.   +7 more
europepmc   +1 more source

Real-world off-label apixaban dosing and clinical outcomes in patients with heart failure and end-stage kidney disease. [PDF]

Medicine (Baltimore)
Im SI, Bae SH, Kim SJ, Kim BJ, Heo JH, Kim YN, Jung Y, Rim H, Cho SP, Park JH, Shin HS.   +10 more
europepmc   +1 more source